From Barchart: 2025-05-06 18:07:00

Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) exceeded revenue expectations in Q1 CY2025, reporting sales of $149.8 million, up 4.3% year on year. However, full-year revenue guidance of $615 million at the midpoint fell short of analysts’ estimates by 1.6%. The company’s GAAP loss of $0.21 per share was significantly below consensus estimates. With a diverse portfolio of eight FDA-approved medications targeting neurological conditions, Supernus Pharmaceuticals develops treatments for epilepsy, ADHD, Parkinson’s disease, and migraine. The company reported a modest year-on-year revenue growth of 4.3% in Q1 but missed on EPS. Operating margin was -6.8%.



Read more at Barchart: Supernus Pharmaceuticals’s (NASDAQ:SUPN) Q1 Sales Beat Estimates But Full-Year Sales Guidance Misses Expectations